[1] Zampino R, Boemio A, Sagnelli C, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol, 2015, 21:11941-11953. [2] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版). 临床肝胆病杂志, 2019, 35:38-44. [3] 孙超. 急性乙型肝炎前驱期发热与肝衰竭的相关性研究 [硕士]: 山东大学, 2013. [4] Lee HC. Acute liver failure related to hepatitis B virus. Hepatol Res, 2008, 38:S9-S13. [5] Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat, 2006, 13:256-263. [6] Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci, 2010, 55:775-783. [7] Yu JW, Sun LJ, Yan BZ, et al. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int, 2011, 31:499-506. [8] Dao DY, Seremba E, Ajmera V, et al. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci, 2012, 57:1349-1357. [9] Fujiwara K, Yasui S, Haga Y, et al. Early combination therapy with corticosteroid and nucleoside analogue induces rapid resolution of inflammation in acute liver failure due to transient hepatitis B virus infection. Intern Med, 2018, 57:1543-1552. [10] Saliba F, Camus C, Durand F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med, 2013, 159:522-531. [11] Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol, 2016, 64:69-78. |